MTOR and metastatic neoplasm: Rapamycin is a classic inhibitor of mTOR, and previous research has shown that this inhibitor inhibits growth and angiogenesis in metastatic tumors by reducing VEGF production and blocking VEGF-induced endothelial cell signaling in a CT-26 cell-transplanted tumor model (32).